Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979559743> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2979559743 endingPage "vi139" @default.
- W2979559743 startingPage "vi138" @default.
- W2979559743 abstract "Abstract The efficacy of FOLFIRI+AFL therapy in the 2nd line for metastatic colorectal cancer was proved in VELOUR study. In Japan, Aflibercept (AFL) was permitted by health insurance medical treatment in 2017. But at that time, many patients had finished the strong chemotherapy or treated after 3rd line chemotherapy. So some patients hoped for the treatment of FOLFIRI+AFL. We study of 4 cases of metastatic colorectal cancer treated by FOLFIRI+AFL after 3rd line in our hospital. Case 1 38 y.o male contracted multiple lung and liver metastases of rectal cancer. He was treated by the following chemotherapies [CAPOX+BEV, FOLFIRI+BEV, FOLFOX+BEV, FTD/TPI] and ALF was introduced in 5th line. 14 courses of FOLFIRI+AFL were performed and the tumors temporarily reduced. Case 2 72 y.o female contracted multiple lymphnode metastases and peritoneal dissemination of sigmoid colon cancer. She was treated by the following chemotherapies [FOLFOX+CET, FOLFIRI+BEV] and ALF was introduced in 3rd line. 3 courses of FOLFIRI+AFL were performed but the tumors were increased (PD). Case 3 67 y.o female contracted unresectable rectal cancer and multiple lymphnode metastases. She was treated by the following chemotherapies [CAPOX+BEV, FOLFIRI+RAM] and ALF was introduced in 3rd line. 1 course of FOLFIRI+AFL was performed, but she deteriorated into bad condition and this therapy was stopped. Case 4 64 y.o female contracted paraaortic lymphnode metastases of rectal cancer . He was treated by the following chemotherapies [FOLFOX+CET, FOLFIRI+BEV, FOLFIRI+PANI] and ALF was introduced in 4th line. 3 courses of FOLFIRI+AFL were performed but the tumors were increased (PD). Conclusion Only Case1 showed tumor regression. But the other 3 cases those were treated by FOLFIRI + molecularly targeted agents except AFL in previous line, showed no efficacy. It is suggested that only exchange of molecularly targeted agents to AFL in FOLFIRI therapy dose not show the enough antitumor effect in colorectal cancer." @default.
- W2979559743 created "2019-10-18" @default.
- W2979559743 creator A5074397360 @default.
- W2979559743 creator A5076203346 @default.
- W2979559743 date "2019-10-01" @default.
- W2979559743 modified "2023-09-23" @default.
- W2979559743 title "4 cases of metastatic colorectal cancer treated by FOLFIRI+Aflibercept (FOLFIRI+AFL) after 3rd line" @default.
- W2979559743 doi "https://doi.org/10.1093/annonc/mdz343.096" @default.
- W2979559743 hasPublicationYear "2019" @default.
- W2979559743 type Work @default.
- W2979559743 sameAs 2979559743 @default.
- W2979559743 citedByCount "0" @default.
- W2979559743 crossrefType "journal-article" @default.
- W2979559743 hasAuthorship W2979559743A5074397360 @default.
- W2979559743 hasAuthorship W2979559743A5076203346 @default.
- W2979559743 hasBestOaLocation W29795597431 @default.
- W2979559743 hasConcept C121608353 @default.
- W2979559743 hasConcept C126322002 @default.
- W2979559743 hasConcept C141071460 @default.
- W2979559743 hasConcept C143998085 @default.
- W2979559743 hasConcept C2776694085 @default.
- W2979559743 hasConcept C2776705615 @default.
- W2979559743 hasConcept C2777802072 @default.
- W2979559743 hasConcept C2778260052 @default.
- W2979559743 hasConcept C2778749236 @default.
- W2979559743 hasConcept C2780259306 @default.
- W2979559743 hasConcept C2780456651 @default.
- W2979559743 hasConcept C2780962732 @default.
- W2979559743 hasConcept C526805850 @default.
- W2979559743 hasConcept C71924100 @default.
- W2979559743 hasConceptScore W2979559743C121608353 @default.
- W2979559743 hasConceptScore W2979559743C126322002 @default.
- W2979559743 hasConceptScore W2979559743C141071460 @default.
- W2979559743 hasConceptScore W2979559743C143998085 @default.
- W2979559743 hasConceptScore W2979559743C2776694085 @default.
- W2979559743 hasConceptScore W2979559743C2776705615 @default.
- W2979559743 hasConceptScore W2979559743C2777802072 @default.
- W2979559743 hasConceptScore W2979559743C2778260052 @default.
- W2979559743 hasConceptScore W2979559743C2778749236 @default.
- W2979559743 hasConceptScore W2979559743C2780259306 @default.
- W2979559743 hasConceptScore W2979559743C2780456651 @default.
- W2979559743 hasConceptScore W2979559743C2780962732 @default.
- W2979559743 hasConceptScore W2979559743C526805850 @default.
- W2979559743 hasConceptScore W2979559743C71924100 @default.
- W2979559743 hasLocation W29795597431 @default.
- W2979559743 hasOpenAccess W2979559743 @default.
- W2979559743 hasPrimaryLocation W29795597431 @default.
- W2979559743 hasVolume "30" @default.
- W2979559743 isParatext "false" @default.
- W2979559743 isRetracted "false" @default.
- W2979559743 magId "2979559743" @default.
- W2979559743 workType "article" @default.